Patents by Inventor MARK WOGULIS

MARK WOGULIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11053489
    Abstract: The present invention relates to cellobiohydrolase variants, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of producing and using the variants.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: July 6, 2021
    Assignee: NOVOZYMES A/S
    Inventors: Mark Wogulis, Leslie Demars, Aubrey Jones, Hanshu Ding, David Osborn
  • Publication number: 20200325463
    Abstract: The present invention relates to cellobiohydrolase variants, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of producing and using the variants.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 15, 2020
    Applicant: Novozymes A/S
    Inventors: Mark Wogulis, Leslie Demars, Aubrey Jones, Hanshu Ding, David Osborn
  • Publication number: 20200299664
    Abstract: The present invention relates to cellobiohydrolase variants having increased thermal activity or thermostability, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: March 24, 2017
    Publication date: September 24, 2020
    Applicant: Novozymes A/S
    Inventors: Mark Wogulis, Leslie DeMars, David Osborn
  • Patent number: 10738293
    Abstract: The present invention relates to cellobiohydrolase variants, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of producing and using the variants.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: August 11, 2020
    Assignee: Novozymes A/S
    Inventors: Mark Wogulis, Leslie Demars, Aubrey Jones, Hanshu Ding, David Osborn
  • Publication number: 20190263715
    Abstract: The present invention relates to xylanase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: April 29, 2019
    Publication date: August 29, 2019
    Applicant: NOVOZYMES A/S
    Inventor: Mark Wogulis
  • Patent number: 10316309
    Abstract: The present invention relates to xylanase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: June 11, 2019
    Assignee: NOVOZYMES A/S
    Inventor: Mark Wogulis
  • Publication number: 20190153414
    Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: February 6, 2019
    Publication date: May 23, 2019
    Applicants: Novozymes, Inc.
    Inventors: Janine Lin, Doreen Bohan, Michelle Maranta, Leslie Beresford, Michael Lamsa, Matt Sweeney, Mark Wogulis, Elizabeth Znameroski, Frank Winther Rasmussen
  • Patent number: 10260058
    Abstract: The present invention relates to beta-glucosidase variants, e.g., beta-glucosidase variants of a parent Family GH3A beta-glucosidase from Aspergillus fumigatus. The present invention also relates to polynucleotides encoding the beta-glucosidase variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the beta-glucosidase variants.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: April 16, 2019
    Assignee: Novozymes, Inc.
    Inventors: Mark Wogulis, Paul Harris, David Osborn
  • Patent number: 10246691
    Abstract: The present invention relates to variants of GH61 polypeptides having cellulolytic enhancing activity, wherein the variants comprise a substitution at one or more positions corresponding to positions 90, 131, 134, and 141 of the full-length polypeptide of SEQ ID NO: 2, and have cellulolytic enhancing activity. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: April 2, 2019
    Assignee: Novozymes, Inc.
    Inventors: Matthew Sweeney, Mark Wogulis
  • Publication number: 20190085309
    Abstract: The present invention relates to cellobiohydrolase variants, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of producing and using the variants.
    Type: Application
    Filed: March 2, 2017
    Publication date: March 21, 2019
    Applicant: Novozymes A/S
    Inventors: Mark Wogulis, Leslie Demars, Aubrey Jones, Hanshu Ding, David Osborn
  • Patent number: 10227579
    Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: March 12, 2019
    Assignees: Novozymes A/S, Novozymes, Inc.
    Inventors: Janine Lin, Doreen Bohan, Michelle Maranta, Leslie Beresford, Michael Lamsa, Matt Sweeney, Mark Wogulis, Elizabeth Znameroski, Frank Winther Rasmussen
  • Patent number: 10221405
    Abstract: The present invention relates to isolated polypeptides having amylolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: March 5, 2019
    Assignee: NOVOZYMES, INC.
    Inventors: Paul Harris, Mark Wogulis
  • Publication number: 20190055532
    Abstract: The present invention relates to variants of a parent cellobiohydrolase II. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: November 1, 2018
    Publication date: February 21, 2019
    Applicant: Novozymes, Inc.
    Inventor: Mark Wogulis
  • Patent number: 10144920
    Abstract: The present invention relates to variants of a parent cellobiohydrolase II. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: December 4, 2018
    Assignee: Novozymes, Inc.
    Inventor: Mark Wogulis
  • Patent number: 10036050
    Abstract: The present invention relates to cellobiohydrolase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of producing and using the variants.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: July 31, 2018
    Assignee: Novozymes, Inc.
    Inventor: Mark Wogulis
  • Patent number: 9879244
    Abstract: The present invention relates to xylanase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: January 30, 2018
    Assignee: NOVOZYMES A/S
    Inventor: Mark Wogulis
  • Publication number: 20170355972
    Abstract: The present invention relates to xylanase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: August 24, 2017
    Publication date: December 14, 2017
    Applicant: NOVOZYMES A/S
    Inventor: Mark Wogulis
  • Patent number: 9816082
    Abstract: The present invention relates to polypeptide having cellulolytic enhancing activity variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: November 14, 2017
    Assignee: Novozymes, Inc.
    Inventors: Matt Sweeney, Mark Wogulis
  • Publication number: 20170306312
    Abstract: The present invention relates to beta-glucosidase variants, e.g., beta-glucosidase variants of a parent Family GH3A beta-glucosidase from Aspergillus fumigatus. The present invention also relates to polynucleotides encoding the beta-glucosidase variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the beta-glucosidase variants.
    Type: Application
    Filed: June 8, 2017
    Publication date: October 26, 2017
    Inventors: Mark Wogulis, Paul Harris, David Osborn
  • Patent number: 9688975
    Abstract: The present invention relates to beta-glucosidase variants, e.g. beta-glucosidase variants of a parent Family GH3A beta-glucosidase from Aspergillus fumigatus. The present invention also relates to polynucleotides encoding the beta-glucosidase variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the beta-glucosidase variants.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: June 27, 2017
    Assignee: Novozymes, Inc.
    Inventors: Mark Wogulis, Paul Harris, David Osborn